- The STEP 1 trial showed an average weight loss of 14.9% of body weight over 68 weeks with Wegovy
- Real-world data (SHAPE study) shows 10–12% average loss — still clinically significant
- Results depend heavily on adherence, protein intake, exercise, and structured clinical support
- The SELECT trial demonstrated a 20% reduction in cardiovascular events independent of weight loss
- Weight regain is common after stopping — long-term treatment is often the most effective strategy
The STEP 1 trial: the landmark result
The STEP 1 trial is the most widely cited study on Wegovy (semaglutide 2.4 mg) for weight loss. Published in the New England Journal of Medicine in 2021, it enrolled 1,961 adults with obesity or overweight with at least one weight-related condition. All participants received lifestyle counseling alongside treatment.
After 68 weeks, participants taking Wegovy lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. Nearly one in three patients lost 20% or more of their starting weight — a result that was largely unprecedented for a medication-based intervention.
For a person starting at 230 lbs, a 14.9% loss translates to approximately 34 lbs over 68 weeks. These are averages — individual results ranged widely, and the trial included structured lifestyle counseling for all participants.
The STEP 1 trial established semaglutide 2.4 mg as one of the most effective non-surgical weight loss treatments studied to date. But averages are just part of the story — your results will depend on your starting weight, health history, medication adherence, and how well the broader treatment plan is followed.
Oral Wegovy: what we know so far
The OASIS clinical trial program studied oral semaglutide for weight management. The OASIS 1 trial (50 mg dose) showed weight loss of approximately 15.1% at 68 weeks, while the OASIS 4 trial (25 mg — the FDA-approved dose) demonstrated approximately 13.6% weight loss at 64 weeks. Both results are comparable to the injectable form.
This is significant because it could offer an alternative for patients who prefer not to self-inject. However, oral Wegovy has specific dosing requirements: it must be taken on an empty stomach with a small amount of water, and patients must wait at least 30 minutes before eating or taking other medications.
An oral formulation of semaglutide (Wegovy Pill) has received FDA approval for chronic weight management, offering a tablet alternative to the injectable form. At PEAK, we have incorporated it into our treatment protocols as an option for eligible patients.
Expected weight loss by starting weight
One of the most common questions patients ask is what their specific weight loss might look like. While individual results vary significantly, the table below provides estimated ranges based on the STEP 1 trial average of approximately 15% body weight loss.
| Starting weight | Estimated loss (15%) | Approximate result |
|---|---|---|
| 180 lbs | ~27 lbs | ~153 lbs |
| 200 lbs | ~30 lbs | ~170 lbs |
| 230 lbs | ~34 lbs | ~196 lbs |
| 260 lbs | ~39 lbs | ~221 lbs |
| 300 lbs | ~45 lbs | ~255 lbs |
These are estimates based on clinical trial averages. Some patients lose more, some less. Factors like metabolic health, medication adherence, protein intake, and physical activity all influence individual outcomes.
Real-world results: the SHAPE study
Clinical trials are conducted under controlled conditions, so it is important to also look at real-world data. The SHAPE study, published in 2024, analyzed electronic health records of over 25,000 adults prescribed semaglutide in clinical practice.
The findings showed that real-world weight loss averaged about 14% of body weight at one year — close to the 15% seen in STEP 1, though individual results varied. Differences in adherence, follow-up frequency, and the availability of structured lifestyle counseling in clinical settings all influence real-world outcomes.
The difference between clinical trial results and real-world outcomes often comes down to one thing: the quality of the support system around the medication.
This is precisely why PEAK emphasizes a structured, clinician-led approach. Medication alone is a tool. When combined with regular check-ins, nutrition guidance, and accountability, patients tend to achieve results closer to what the clinical trials demonstrate.
Factors that influence your results
No two patients respond to Wegovy the same way. Understanding the variables can help set realistic expectations and help your care team tailor your treatment plan.
Starting BMI and metabolic health
Patients with higher starting BMIs sometimes lose more total weight but a similar percentage of body weight. Metabolic factors like insulin resistance, thyroid function, and existing medications can also influence response.
Medication adherence and dose titration
Wegovy uses a gradual dose titration over 16–20 weeks to reach the maintenance dose of 2.4 mg weekly. Patients who complete the full titration and maintain consistent dosing tend to see better outcomes. Missed doses or interruptions can reduce effectiveness.
Nutrition and protein intake
GLP-1 medications reduce appetite significantly, which can lead to under-eating and muscle loss if protein intake is not prioritized. Consuming 1.2–1.6 grams of protein per kilogram of goal body weight helps preserve lean mass during weight loss.
Physical activity and resistance training
Exercise, particularly resistance training, plays a critical role in preserving muscle mass during GLP-1-assisted weight loss. Patients who incorporate regular strength training tend to lose a higher proportion of fat versus lean tissue.
Sleep and stress management
Poor sleep and chronic stress elevate cortisol, which can counteract weight loss efforts. Your PEAK care team may address these factors as part of your overall treatment plan.
Weight loss timeline: what to expect month by month
Understanding the timeline helps manage expectations. Weight loss with Wegovy is not linear — it follows a general pattern of gradual acceleration during titration, peak loss during maintenance dosing, and eventual plateau.
| Timeframe | Typical experience |
|---|---|
| Weeks 1–4 | Starting dose (0.25 mg); mild appetite reduction; 1–3 lbs lost; GI adjustment period |
| Months 2–3 | Increasing doses; more noticeable appetite suppression; 5–10 lbs cumulative |
| Months 4–6 | Approaching or reaching maintenance dose (2.4 mg); steady loss of 3–5 lbs/month |
| Months 6–12 | Peak weight loss phase; most patients reach 10–15% total loss |
| Months 12–18 | Weight loss slows or plateaus; focus shifts to maintenance and habit solidification |
The SELECT trial: cardiovascular benefits
In 2023, the SELECT trial demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 20% in adults with overweight or obesity and established cardiovascular disease.
This was a landmark finding because it showed that semaglutide benefits extend beyond weight loss. The cardiovascular protection appears to occur through multiple mechanisms, including reduced inflammation, improved blood vessel function, and metabolic improvements.
The SELECT trial changed how clinicians think about GLP-1 medications. Weight loss is no longer the only reason to consider treatment — cardiovascular risk reduction is now an independent benefit supported by rigorous evidence.
Wegovy vs. Zepbound: how do results compare?
Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist that works on two hormonal pathways rather than one. In the SURMOUNT-5 head-to-head trial, tirzepatide produced greater average weight loss than semaglutide — approximately 20.2% versus 13.7% at 72 weeks.
However, comparing medications is not as simple as looking at average weight loss percentages. The right medication depends on your individual health profile, insurance coverage, side effect tolerance, and clinical goals. Some patients respond better to one medication than the other.
At PEAK, medication selection is always a clinical decision made in collaboration with your care team — not a one-size-fits-all protocol.
What happens when you stop Wegovy?
The STEP 1 extension trial followed participants after they discontinued semaglutide. Within one year of stopping, patients regained approximately two-thirds of the weight they had lost. This is consistent with the understanding that obesity is a chronic condition requiring ongoing management.
Weight regain after stopping is not a failure of willpower — it reflects the body's biological drive to return to a higher weight set point. Hormonal changes, including increases in appetite hormones and decreases in metabolic rate, contribute to regain.
If you and your clinician decide to taper or stop Wegovy, the process is gradual and supported. We work to establish behavioral foundations — nutrition habits, exercise routines, and monitoring systems — that help preserve as much progress as possible.
For many patients, long-term or maintenance-dose treatment is the most effective strategy. This is a conversation you will have with your PEAK clinician based on your progress and goals.
Setting realistic expectations
Wegovy is the most effective FDA-approved weight loss medication available as a single-agonist GLP-1. But effectiveness depends on context. The patients who achieve the best outcomes at PEAK share a few common traits:
- They attend regular check-ins and follow their titration schedule
- They prioritize protein intake and follow their nutrition plan
- They incorporate resistance training at least 2–3 times per week
- They communicate openly with their care team about side effects and challenges
- They view medication as one component of a broader health strategy
The medication creates the window of opportunity. What you do inside that window determines the outcome.
Important safety information: Wegovy carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on animal studies. It is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Discuss your full medical history with your clinician before starting treatment.
If you are considering Wegovy, the best next step is a conversation with a clinician who can evaluate your specific situation and help you understand what realistic results might look like for you.
